Gitane Patel, MD
Ophthalmology · San Diego, CANPI 1710171434
Payments from drug & device makers
Across 292 payments — averaging $33.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Oyster Point Pharma, Inc.$820
- Sun Pharmaceutical Industries Inc.$601
- Novartis$596
- Eyevance Pharmaceuticals LLC$586
- NEW World Medical,inc.$567
- plus $5K from 20 others
What the payments were for
- Food & beverage$9,799100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 52 | $1,910 |
| Oyster Point Pharma, Inc. | 13 | $820 |
| Sun Pharmaceutical Industries Inc. | 27 | $601 |
| Novartis | 48 | $596 |
| Eyevance Pharmaceuticals LLC | 27 | $586 |
| NEW World Medical,inc. | 2 | $567 |
| Bausch & Lomb Americas Inc. | 15 | $537 |
| Glaukos Corporation | 4 | $510 |
| Tarsus Pharmaceuticals, Inc. | 7 | $472 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $446 |
| Aerie Pharmaceuticals, Inc. | 19 | $425 |
| Kala Pharmaceuticals, Inc. | 15 | $405 |
| Mallinckrodt Hospital Products Inc. | 12 | $336 |
| Dompe US, Inc. | 4 | $333 |
| AbbVie(2 entities) | 14 | $308 |
| Amgen(2 entities) | 6 | $302 |
| Harrow Eye, LLC | 6 | $157 |
| Rxsight Inc | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 1 | $118 |
| Shire North American Group Inc | 2 | $37 |
| Sight Sciences, Inc. | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Thea Pharma Inc. | 1 | $18 |
| Beaver-visitec International, Inc. | 1 | $18 |
| Omeros Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYRVAYA$429
- iDose$377
- Rhopressa$364
- Kahook Dual Blade$309
- Streamline Surgical System$309
- Ahmed Glaucoma Valve$309
- XDEMVY$308
- Oxervate$270
- MIEBO$248
- TEPEZZA$245
- Rocklatan$238
- INVELTYS$150
- EYSUVIS$150
- Clareon PanOptix Pro$146
- Hydrus Microstent$138
- TRYPTYR$132
- XIIDRA$125
- RXSIGHT CONTACT LENS$125
- RXSIGHT INJECTOR CARTRIDGE$125
- RXSIGHT INJECTOR HANDPIECE$125
How this compares
$9,824 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 378 | $348,557 |
| XiidraLifitegrast | 260 | $278,477 |
| TyrvayaVarenicline Tartrate | 158 | $144,212 |
| Cyclosporine | 344 | $127,701 |
| MieboPerfluorohexyloctane/Pf | 76 | $77,567 |
| CombiganBrimonidine Tartrate/Timolol | 93 | $29,855 |
| LumiganBimatoprost | 68 | $24,492 |
| EysuvisLoteprednol Etabonate | 48 | $23,682 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 118 | $21,966 |
| RocklatanNetarsudil Mesylat/Latanoprost | 32 | $16,057 |
| RhopressaNetarsudil Mesylate | 18 | $15,853 |
| Latanoprost | 1,106 | $14,583 |
| VyzultaLatanoprostene Bunod | 32 | $14,267 |
| Prednisolone Acetate | 386 | $11,607 |
| Loteprednol Etabonate | 31 | $8,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $308 | $402,904539 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $537 | $370,310368 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $820 | $144,212158 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $425 | $31,91050 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $405 | $23,68248 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $446 | $8,23431 claims |
| AlconSimbrinza | $1,910 | $4,96815 claims |
| Eyevance Pharmaceuticals LLCFlarex | $586 | $2,38518 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $125 | $56844 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Diego
- William FreemanSan Diego$997K
- Eric NudlemanSan Diego$752K
- Robert WeinrebSan Diego$660K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.